Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of CSL112 in Acute Coronary Syndrome
2017-000996-98Phase 3Suspended
- Sponsor
- CSL Behring
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) and myocardial infarction (MI) comparing CSL112 with Placebo (2 arms). Primary endpoint: Time to first MACE event. Started May 2018; status: suspended.
02
Drugs
CSL112
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on 2017-000996-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000996-98.